Cara Therapeutics Shows Rising Relative Strength; Still Shy Of Key Threshold

Cara Therapeutics (CARA) had its Relative Strength (RS) Rating upgraded from 70 to 73 Thursday — a welcome improvement, but still shy of the 80 or better score you prefer to see.


When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength.

This exclusive rating from Investor’s Business Daily measures market leadership with a 1 (worst) to 99 (best) score. The grade shows how a stock’s price performance over the trailing 52 weeks compares to all the other stocks in our database.

Over 100 years of market history shows that the top-performing stocks tend to have an 80 or higher RS Rating in the early stages of their moves. See if Cara Therapeutics can continue to show renewed price strength and clear that threshold.

Looking For The Best Stocks To Buy And Watch? Start Here

Cara Therapeutics is working on a cup without handle with a 22.70 entry. See if the stock can clear the breakout price in heavy volume.

Regarding top and bottom line numbers, the company has posted rising EPS growth in each of the last five reports. Revenue growth has also moved higher over the same time frame.

The company holds the No. 7 rank among its peers in the Medical-Biomed/Biotech industry group. Ligand Pharmaceuticals (LGND) and Vericel (VCEL) are also among the group’s highest-rated stocks.


Biotech And Pharmaceutical Industry And Stock News

IBD Stock Rating Upgrades: Rising Relative Strength

Why Should You Use IBD’s Relative Strength Rating?

How Relative Strength Line Can Help You Judge A Stock

See How To Reduce Risk, Increase Profits With Swing Trading

Most Related Links :
todayuknews Governmental News Finance News

Source link

Back to top button